Gilead Sciences (GILD) Stock Movement Summary Gilead Sciences stock rallied following several positive developments: Q4 2025 Results: - Q4 sales reached $7.92 billion, up 5% year-over-year and exceeding estimates of $7.57 billion - Adjusted EPS of $1.86 topped expectations of $1.83 - Full-year 2025 EPS spiked 76% to $8.15 versus $4.62 in 2024 - Annual sales increased 2% to $29.44 billion Forward Guidance: - FY26 sales guidance: $29.6-$30 billion - FY26 EPS guidance: $8.45-$8.85 Product Developments: - HIV franchise sales grew 6%, driven by Biktarvy and Descovy demand - Liver disease revenue rose 17%, led by Livdelzi - FDA expanded Yescarta CAR T-cell therapy label to include relapsed or refractory primary central nervous system lymphoma (PCN
Read full analysisGilead Sciences (GILD) Stock Movement Summary Gilead Sciences stock rallied following several positive developments: Q4 2025 Results: - Q4 sales reached $7.92 billion, up 5% year-over-year and exceeding estimates of $7.57 billion - Adjusted EPS of $1.86 topped expectations of $1.83 - Full-year 2025 EPS spiked 76% to $8.15 versus $4.62 in 2024 - Annual sales increased 2% to $29.44 billion Forward Guidance: - FY26 sales guidance: $29.6-$30 billion - FY26 EPS guidance: $8.45-$8.85 Product Developments: - HIV franchise sales grew 6%, driven by Biktarvy and Descovy demand - Liver disease revenue rose 17%, led by Livdelzi - FDA expanded Yescarta CAR T-cell therapy label to include relapsed or refractory primary central nervous system lymphoma (PCN
Gilead Sciences is a major biopharmaceutical company best known for its HIV treatment and prevention drugs, including Biktarvy and Descovy, as well as liver disease therapies. The company also has a growing oncology portfolio anchored by the CAR T-cell therapy Yescarta and is currently launching Yeztugo, a new HIV treatment that analysts view as a significant growth driver.